Investors might have begun to worry that Fulgent Genetics' (NASDAQ: FLGT) freefall in recent months would never end. The genetic testing company's shares have plunged more than 50% from the highs set earlier this year. Fulgent announced its first-quarter results after the market closed Thursday.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting